Clinical value of a patient-reported goal-attainment measure: the global development of self-assessment goal achievement (SAGA) questionnaire for patients with lower urinary tract symptoms

Authors


  • Christopher Chapple led the peer-review process as the Associate Editor responsible for the paper.
  • V.K. is a consultant to Pfizer, Astellas, and Allergan. M.E. is a consultant to Pfizer and Astellas. D.M.K. is a consultant to Pfizer, Ferring, Astellas, Bayer, and Lilly. A.F.J. has nothing to declare. C.K. is a consultant to Pfizer, Astellas, and Allergan. L.B. has nothing to declare. J.B. is a consultant to Pfizer, GlaxoSmithkline, Astra Zeneca, BMS, Regemeron, and Merck. L.P. is an employee of Adelphi Values (formerly Mapi Values) who were paid consultants to Pfizer Inc. J.T. is an employee of Pfizer Inc.

Abstract

Aims

To discuss the importance of patients' treatment goals and perceived goal attainment to better address expectations in the treatment of lower urinary tract symptoms (LUTS), including overactive bladder (OAB).

Methods

The development of the Self-Assessment Goal Achievement (SAGA) questionnaire was driven by measurement principles from the field of qualitative and psychometric research adapted to elicit patients' treatment goals. At baseline, SAGA solicits individualized responses of patient's treatment expectations and goals, and at follow-up SAGA uses a goal-attainment scale (GAS) to document goal achievement.

Results

The SAGA questionnaire provides a basis for the patient and physician to discuss realistic treatment expectations and to measure the alignment between patients' expectations and treatment outcomes in terms of improvement in symptoms and impact on function. Therefore, incorporating the SAGA questionnaire into clinical trials may provide an additional dimension of treatment efficacy by incorporating data on treatment satisfaction from the patient's perspective.

Conclusions

The SAGA questionnaire is a useful tool for patient-centered discussions about the treatment and management of LUTS, including OAB, and assisting physicians in tracking progress and managing patient expectations during therapy. Neurourol. Urodynam. 33:90–94, 2014. Copyright © 2013 Wiley Periodicals, Inc.

Ancillary